BlossomHill Therapeutics (NASDAQ:BLSM) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of BlossomHill Therapeutics (NASDAQ:BLSM) to a hold rating in a report published on Saturday morning.

BlossomHill Therapeutics Stock Up 1.2%

Shares of NASDAQ:BLSM opened at $16.38 on Friday. BlossomHill Therapeutics has a one year low of $15.25 and a one year high of $17.25.

Insider Buying and Selling

In other news, Director John P. Schmid acquired 6,000 shares of BlossomHill Therapeutics stock in a transaction dated Monday, August 10th. The shares were purchased at an average cost of $16.00 per share, for a total transaction of $96,000.00. Following the transaction, the director owned 6,000 shares of the company’s stock, valued at $96,000. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, General Counsel Vincent Paul Liptak acquired 2,500 shares of BlossomHill Therapeutics stock in a transaction dated Friday, August 7th. The shares were purchased at an average price of $15.80 per share, for a total transaction of $39,500.00. Following the completion of the transaction, the general counsel directly owned 109,212 shares in the company, valued at approximately $1,725,549.60. The trade was a 2.34% increase in their position. The SEC filing for this purchase provides additional information. Insiders bought 1,573,900 shares of company stock valued at $25,181,900 in the last three months.

About BlossomHill Therapeutics

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.